Myriad Genetics Tries To Ditch Billing Fraud Stock Drop Suit

By Reenat Sinay (October 31, 2018, 9:12 PM EDT) -- Myriad Genetics Inc. and its directors asked a Utah federal judge to throw out a securities fraud class action against them on Tuesday, claiming that investors relied on an "armchair legal opinion" in their failure to adequately argue that the company illegally overbilled Medicare for its cancer testing services....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!